Related Experiment Video
Updated: Aug 1, 2026
09:09
A Method for Targeted 16S Sequencing of Human Milk Samples
Published on: March 23, 2018
Aztreonam in human serum and breast milk
British Journal of Clinical Pharmacology
|April 1, 1985
Summary
This study found that aztreonam concentrations in breast milk are significantly lower than in serum after both IV and IM administration. These low levels suggest minimal risk to nursing infants.
Area of Science:
- Pharmacokinetics
- Antibiotic Therapy
- Lactational Pharmacology
Background:
- Aztreonam is a monobactam antibiotic used for serious infections.
- Understanding drug transfer into breast milk is crucial for lactating women.
Purpose of the Study:
- To quantify aztreonam concentrations in maternal serum and breast milk.
- To assess the potential risk of aztreonam exposure to nursing infants.
Main Methods:
- 12 healthy lactating women received a single 1g dose of aztreonam (intramuscular or intravenous).
- Serum and milk samples were collected over 8 hours post-dose.
- Aztreonam concentrations were measured using validated analytical methods.
Main Results:
- Milk aztreonam concentrations were consistently lower than serum concentrations.
- Peak milk concentrations were less than 1% of peak serum concentrations.
- Time to peak concentration was significantly longer in milk compared to serum.
Conclusions:
- Aztreonam exhibits low transfer into breast milk.
- Combined with poor oral bioavailability, this indicates a low risk for nursing infants.
- Aztreonam is likely safe for use in breastfeeding mothers.
